Nephrology

Renal Transplant Maintenance

Advertisement

Patient Care Perspectives Podcast: Educating Patients and Clinicians on the Future of Kidney Transplantation

patient care perspectives by Flavio G. Vincenti, MD
Overview

Kidney transplantation can transform quality of life, but long-term maintenance therapy still requires clinicians to balance effective immunosuppression against toxicity, graft function, rejection risk, and patient burden. In today’s podcast, Flavio G. Vincenti, MD, discusses the current role of calcineurin inhibitors, the evolving roles of belatacept and other biologic strategies, and the importance of measured patient education about emerging technologies such as xenotransplantation and bioartificial kidneys.

 

References

Chandran S, Vincenti F. Antiplasma cell antibodies: a new era of human leukocyte antigen antibody control in solid organ transplantation. Am J Transplant. 2025;25(1):19-26. doi:10.1016/j.ajt.2024.10.005

 

Crannell WC, Perkins JD, Leca N, Kling CE. Deceased donor kidneys are discarded at higher rates when labeled as high kidney donor profile index. Am J Transplant. 2022;22(12):3087-3092. doi:10.1111/ajt.17197

 

Kawai T, Williams WW, Elias N, et al. Xenotransplantation of a porcine kidney for end-stage kidney disease. N Engl J Med. 2025;392(19):1933-1940. doi:10.1056/NEJMoa2412747

 

Vincenti F, Shoji J, Wojciechowski D, et al. Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection. Am J Transplant. 2026;26(4):797-806. doi:10.1016/j.ajt.2025.12.290

Flavio G. Vincenti, MD

Clinical Professor of Medicine and Surgery
Department of Medicine
Kidney Transplant Service
University of California, San Francisco
San Francisco, CA

Advertisement